Develops novel anti-infectives and immunotherapies to treat serious fungal and viral infections.
Cidara Therapeutics, Inc., headquartered in San Diego, California, is a leading biotechnology company specializing in the discovery, development, and commercialization of long-acting anti-infectives. The company's primary focus is on addressing infectious diseases and oncology through innovative therapies in the United States.
At the forefront of Cidara's pipeline is rezafungin acetate, a pioneering molecule belonging to the echinocandin class of antifungals. This novel compound is specifically developed for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, conditions associated with high mortality rates. In addition to rezafungin acetate, Cidara advances its Cloudbreak platform, aimed at developing conjugates to combat a wide spectrum of viral infections such as influenza, RSV, HIV, and various strains of SARS-CoV-2 responsible for COVID-19.
Founded in 2012 and formerly known as K2 Therapeutics, Inc., Cidara Therapeutics has established itself as a pioneer in biopharmaceutical innovation. The company continues to expand its research and development efforts, leveraging strategic partnerships and cutting-edge technologies to advance transformative therapies that address critical medical needs globally.